Table of Contents
About This Report The Canadian generic drugs industry faces a number of challenges, although provinces are now implementing strategies to increase competition in the industry, and provide greater opportunities for smaller generic drugs players. In terms of biosimilars, referred to as subsequent entry biologics (SEBs), Health Canada in March 2010 published its regulatory guidance for the approval of SEBs. What's Included i...More »
The Largest Collection of Market Research Reports
From +200,000 authoritative sources
Talk to Alison
00 1 718 618 48 97
PharmaSphere: Global Generics Strategy - Key Drivers, Markets and Trends in 2013 Summary GlobalData's "PharmaSphere: Global Generics Strategy - Key Drivers, Markets and Trends in 2013" report, provides ...
Introduction What are the implications for regulators, biosimilar companies and branded manufacturers? There are few areas of the pharmaceutical market more hotly debated than biosimilars yet the pathway ...
This report is an in-depth financial evaluation of the Global Generic Pharmaceuticals. Using the unique Plimsoll method of analysis, each of the largest 198 companies is individually assessed and ranked ...
... Hale & tempest how to provide affordable medicines in today S competitive global market dr. Brian w tempest www.Briantempest.Com world generic medicines congress london ...
Reportlinker.com © Copyright 2013. All rights reserved.